EFFECT OF COENZYME Q10 ALONE AND ITS COMBINATION WITH ROSUVASTATIN ON STREPTOZOTOCIN-NICOTINAMIDE INDUCED DIABETIC NEUROPATHY IN RATS
Keywords:
Diabetic neuropathy, Coenzyme Q10, Rosuvastatin, Muscular grip strength, Oxidative stressAbstract
Objectives: This study was aimed to investigate the effect of coenzyme Q10 and its combination with rosuvastatin on STZ-nicotinamide induced diabetic neuropathy.
Methods: Diabetic neuropathy in rats were induced with streptozotocin-nicotinamide. The diabetic rats were treated with coenzyme Q10 or rosuvastatin or their combination. Various parameters like muscular grip strength, paw withdrawal response, tail flick response and markers of oxidative stress such as malondialdehyde (MDA) level, superoxide dismutase (SOD) and reduced glutathione (GSH) in the sciatic nerve were measured. All treated animal was subjected to histopathological changes of sciatica nerve.
Results: In diabetic control group, muscular grip strength was significantly decreased and increased paw withdrawal response, tail flick response as compared to normal control rats. In addition, STZ-nicotinamide caused nerve cell damage with a higher MDA level, depletion of SOD and GSH level along with marked degeneration of the nerve cell. The treatment of diabetic rats with coenzyme Q10 or rosuvastatin or their combination ameliorate STZ-nicotinamide induced nerve damage due to improvement in the muscular grip strength, paw withdrawal response, tail flick response, reduction in oxidative stress along with histopathological changes.
Conclusion: This finding suggests that treatment with coenzyme Q10 or rosuvastatin showed significant neuroprotective effect against STZ-nicotinamide induced diabetic neuropathy. However, concomitant administration of both showed a better neuroprotective effect than coenzyme Q10 or rosuvastatin alone treatment.
Â
Downloads
References
Kumar S, Ashe HC, Parnell LN, Fernando DJ, Tsigos C, Young RJ, et al. The prevalence of foot ulceration and its correlates in type 2 diabetes: a population-based study. Diabet Med 1994;11:480–4.
Cabezas-Cerrato J. The prevalence of diabetic neuropathy in Spain: a study in primary care and hospital clinic groups. Diabetol 998;41:1263–9.
Ghosh P, Kandhare AD, Gauba D, Raygude KS, Bodhankar SL. Determination of efficacy, adverse drug reactions and cost effectiveness of three triple drug regimens for the treatment of H. pylori infected acid peptic disease patients. Asian Pac J Trop Biomed 2012;2:S783–S9.
Gilron I, Coderre TJ. Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs 2007:12:113–26.
Clark CM, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Eng J Med 1995;332:1210–7.
Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988;33:11–23.
Abuaisha BB, Costanzi JB, Boulton AJM. Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long term injury. Diabetes Res Clin Pract 1998;39:115–21.
Apfel SC. Introduction to diabetic neuropathy. Am J Med 1999;107:1S.
Baynes JW, Thorpe R. Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes 1999;48:1–9.
Kandhare AD, Raygude KS, Ghosh P, Ghule AE, Bodhankar SL. Neuroprotective effect of naringin by modulation of endogenous biomarkers in streptozotocin induced painful diabetic neuropathy. Fitoterapia 2012;83:650–9.
The Diabetes Control Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy in the diabetes control and complications trial. Ann Int Med 1995;122:561–8.
Niklowitz P, Menke T, Andler W, Okun JG. Simultaneous analysis of coenzyme Q10 in plasma, erythrocytes and platelets: comparison of the antioxidant level in blood cells and their environment in healthy children and after oral supplementation in adults. Clin Chim Acta 2004;342(1-2):219-26.
Ahmadvand H. Effects of coenzyme Q10 on hemoglobin A1C, serum urea and creatinine in alloxan-induced type 1 diabetic rats. Iranian J Pharmacol Ther 2012;11:64-7.
Visnagri A, Kandhare AD, Shiva Kumar V, Rajmane AR, Mohammad A, Ghosh P, et al. Elucidation of ameliorative effect of Co-enzyme Q10 in streptozotocin-induced diabetic neuropathic perturbation by modulation of electrophysiological, biochemical and behavioral markers. Biomed Aging Pathol 2012;2:157-72.
McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002;8(4):1451-8.
Maheshwari RA, Khatri K, Sailor GU, Balaraman R. Antidiabetic activity of Dibolin (a polyherbal formulation) in streptozotocin-nicotinamide induced type 2 diabetic rats. Int J Pharm Pharm Sci 2014;Suppl 2:893-7.
Garjani A, Andalib S, Biabani S. Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat. Eur J Pharmacol 2011;666(1-3):135-41.
Maheshwari RA, Sailor GU, Patel L, Balaraman R. Amelioration of cisplatin-induced nephrotoxicity by statins. Indian J Pharmacol 2013;45(4):354-8.
Woolfe G, MacDonald AD. The evaluation of the analgesic action of pethidine hydrochloride (Demerol). J Pharmacol Exp Ther 1944;80:300-7.
Sharma SS, Kumar A, Kaundal R. 4-Amino 1,8-napthalimide: a potent PARP inhibitor, its neuroprotective role in experimental diabetic neuropathy. Life Sci 2008;82:570–6.
Slater TF, Sawyer BC. The stimulatory effect of carbon tetrachloride and other halogenalkane or peroxidative reaction in the rat liver functions in vitro. Biochem J 1971;123(5):805-15.
Mishra HP, Fridovich I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay of superoxide dismutase. J Biol Chem 1972;247(10):3170-5.
Moron MS, Depierre JW. Levels of glutathione, glutathione reductase and glutathione S transferase activities in rat lung and liver. Biochim Biophys Acta 1979;582(1):67-78.
Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, et al. Pharmacokinetics and pharmacody-namics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88.
National Prescribing Service, August 2010. Sitagliptin for Type 2 Diabetes.http://www.nps.org.au/consumers/publications/medicine_update/issues/sitagliptin.
Kumar A, Kaundal RK, Iyer S, Sharma SS. Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci 2007;80:1236–44.
Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA. Effects of DLalpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000;49:1006–15.
Sayyed SG, Kumar A, Sharma SS. Effects of U83836E on nerve functions, hyperalgesia and oxidative stress in experimental diabetic neuropathy. Life Sci 2006;79:777–83.
Cui XP, Li BY, Gao HQ, Wei N, Wang WL, Lu M. Effects of grape seed proanthocyanidin extracts on peripheral nerves in streptozocin-induced diabetic rats. Nutr Sci Vitaminol 2008;54(4):321-8.
Arora M, Kumar A, Kaundal RK, Sharma SS. Amelioration of neurological and biochemical deficits by peroxynitrite decomposition catalysts in experimental diabetic neuropathy. Eur J Pharmacol 2008;596:77–83.
Saini AK, Kumar HAS, Sharma SS. Preventive and curative effect of edaravone on nerve functions and oxidative stress in experimental diabetic neuropathy. Eur J Pharmacol 2007;568:164–72.